
Eli Lilly (LLY) remains a high-conviction play in the metabolic space as their next-generation "triple agonist" drug, Retatrutide, enters the spotlight with potential weight loss efficacy of up to 24%. Investors should monitor Paramount Global (PARA) as they double down on the "Yellowstone" universe to drive streaming profitability through high-value intellectual property. Palantir (PLTR) continues to solidify its position as a "defense-first" tech giant, though its aggressive stance on national security and military service presents a unique reputational risk profile. The "Westernization" of pop culture suggests a bullish outlook for Live Nation (LYV), which stands to benefit from the surging demand for Southern rock tours and country-themed live events. For those seeking alternative assets, antique firearms from the 17th century currently trade at a perceived market inefficiency, with historical artifacts occasionally priced as low as $400.